Who are Cannabidiol Oral Solution [Epidiolex]'s main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cannabidiol-oral-solution-epidiolex.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Cannabidiol Oral Solution [Epidiolex] — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cannabidiol Oral Solution [Epidiolex] (Cannabidiol Oral Solution [Epidiolex]) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cannabinoid anticonvulsant. Area: Neurology.

marketed Cannabinoid anticonvulsant TRP channels, adenosine signaling, serotonin receptors (multi-target) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Cannabidiol Oral Solution [Epidiolex] (Cannabidiol Oral Solution [Epidiolex]) — Silkiss Eye Surgery. Cannabidiol modulates endocannabinoid signaling and multiple ion channels to reduce neuronal hyperexcitability and seizure activity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cannabidiol Oral Solution [Epidiolex] TARGET	Cannabidiol Oral Solution [Epidiolex]	Silkiss Eye Surgery	marketed	Cannabinoid anticonvulsant	TRP channels, adenosine signaling, serotonin receptors (multi-target)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cannabinoid anticonvulsant class)

Silkiss Eye Surgery · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cannabidiol Oral Solution [Epidiolex] — Competitive Intelligence Brief. https://druglandscape.com/ci/cannabidiol-oral-solution-epidiolex. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab